CONGRESS | #EBMT24
Florent Malard, from Sorbonne Université, delivers an interesting presentation on the early access program (EAP) in Europe and reports on clinical outcomes of patients with SR or SD GI acute #GvHD that were treated with pooled allogeneic microbiotherapy MaaT013.…

Roberto Mina presents the HRQOL results of CARTITUDE-4 in patients with lenalidomide-refractory MM who had 1-3 prior lines of therapy who were treated with ciltacel vs SOC #mmsm
Generalised improvements and label extended in this setting

CONGRESS | #EBMT24 | Rakesh Popat UCL presents on the issues of equity and access to clinical trials in #multiplemyeloma , discussing the factors leading to health disparities as well as the impact of these on outcomes. Dr Popat presents methods to improve diversity in clinical…

#EBMT24 Robert Chiesa: anti-CD7 CAR T cells for children with relapsed T-ALL #leusm #pedonc

Some published data nejm.org/doi/full/10.10…

#EBMT24 Peter Bader presented real world data of anti-CD19 CAR T cells after HCT (a few patients received blinatumomab as bridging therapy) in children with ALL #leusm #pedonc

#EBMT24 Annita Lawitschka presents the new FORUM 2 trial
The first randomisation will address radiation dose and the second randomisation GVHD treatment in children with ALL #leusm #pedonc

News: Study bolsters concerns about US #FDA accelerated #cancerdrug approvals thelancet.com/journals/lanon…

#EBMT24 Mary Horowitz revised the history of HCT: where do we come from?

From Hiroshima to ongoing matching and therapy refinements #bmtsm

Special mention to Eliane Gluckman for being a role model for women in the field

#EBMT24 📣

Good to hear this data presented #EBMT24 👏
EBV+ IS-related PTLD in CNS:
EBV-CTLs Tab-cel
Other Rx options limited (HD-MTX hard to deliver post (renal)SOT) & often challenging clinical situation
Further f-up awaited but encouraging data - esp for ‘responders’ ⁦The EBMT⁩

📢 Call for essays and art: October will mark our 10-year anniversary and we are calling for pieces on the theme 'celebrating our community' ⬇️

We look forward to receiving contributions by July 15!
thelancet.com/journals/lanha…
#hematology #hemonc #patientvoice #artofmedicine

We are still facing many CAR-T access challenges in Europe. Christian Chabannon The EBMT #EMBT24 #EBMTPatientFamilyandDonorDay

A very exciting start to the day- A presentation on the development of guidelines for psychological assessment in HSCT…the whole audience got there phones out to capture this QR code!! You can find the guidelines on the Anthony Nolan website: anthonynolan.org/sites/default/…

#EBMT24

#EBMT24 Dieter Niederwieser presents ph3 trial data on #bmtsm vs observation in older patients (60-75 years) with AML in first remission #leusm
Study by The EBMT, first randomised data in this setting 👏🏽

Good morning from Glasgow! Ready for #EBMT24

If you would like to discuss a submission to The Lancet group or anything else, get in touch!

Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.ly/Q01McRRH0

Attending #EBMT24 ? Yaiza del Pozo Martin, Deputy Editor, invites you to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.ly/Q01McRRH0

Tranexamic Acid for Management of Heavy Vaginal Bleeding: Barriers to Access and Myths Surrounding Its Use - written by brilliant co-first authors Dr Heather VanderMeulen and soon-to-be Dr Grace Tang ⭐️ ⭐️ RPTH doi.org/10.1016/j.rpth…

NEW: Anti-CD30 CAR T-cell infusion as consolidation after BEAM and autologous HSCT is safe, and showed preliminary activity in patients with Hodgkin lymphoma at high risk of relapse (trial included also patients with documented CD30+ NHL) #lymsm

thelancet.com/journals/lanha…